Home
Search
Study Topics
Glossary
|
Study 11 of 63 for search of: | Australia, Australian Capital Territory |
Previous Study | Return to Search Results | Next Study |
|
|
|
|
|
Sponsors and Collaborators: |
Celgene Corporation ICON Clinical Research |
---|---|
Information provided by: | Celgene Corporation |
ClinicalTrials.gov Identifier: | NCT00057616 |
Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase. Subjects are treated in repeating 4 week cycles.
Condition | Intervention | Phase |
---|---|---|
Melanoma Neoplasm Metastasis |
Drug: CC-5013 |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of CC-5013 Vs. Placebo in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2, or IFN Based Therapy |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Study ID Numbers: | CC-5013-MEL-002 |
Study First Received: | April 4, 2003 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00057616 |
Health Authority: | United States: Food and Drug Administration |
Metastatic Melanoma Melanoma Revimid CC5013 |
Neuroectodermal Tumors Nevus, Pigmented Neoplasms, Germ Cell and Embryonal Lenalidomide Neoplasm Metastasis |
Neuroepithelioma Nevus Neuroendocrine Tumors Melanoma |
Neoplastic Processes Neoplasms Pathologic Processes Neoplasms by Histologic Type Antineoplastic Agents |
Therapeutic Uses Neoplasms, Nerve Tissue Nevi and Melanomas Pharmacologic Actions |